null

null

null

null

null

null

null

null

null

null

null

null

null

Minimal long-term debt; relies primarily on equity financing and ATM offerings; near-zero debt leverage ratio typical of pre-revenue clinical-stage biotech

Negligible direct interest rate sensitivity; no significant floating-rate debt; rising rates increase equity dilution cost as cash burn continues

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) Single-source API manufacturing for PV-10 (rose bengal); 2) Specialty pharmaceutical-grade chemical suppliers concentrated in EU/India

Minimal international revenue; clinical operations in Australia expose company to AUD devaluation; no material sovereign currency revenue risk currently

Primarily US-based operations; Australian clinical trial sites add AUD exposure; no significant multi-market revenue footprint established

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single or very limited manufacturers for rose bengal active pharmaceutical ingredient; likely exceeds 30% operational input threshold

Pre-commercial biopharmaceutical; no cloud-infrastructure-dependent revenue engine; disruption would affect internal R&D systems, not revenue delivery

Clinical-stage drug developer; secondary model involves potential licensing/partnerships; cloud termination minimally impacts core drug development pipeline

No significant API coupling risk; company is a drug developer, not a software platform; switching costs relate to CMO relationships, not digital APIs

Low Howey Test risk; equity securities already registered; revenue model is drug commercialization, not token/investment-contract-based fundraising

Very High

Moderate GDPR exposure via EU/Australian clinical trial patient data; CCPA exposure limited; compliance required under ICH-GCP but not primary business risk

Minimal antitrust exposure; single niche oncology asset (PV-10/rose bengal); no market dominance or pricing power warranting regulatory scrutiny

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Currently 0% recurring revenue; pre-commercial stage with no product sales; 100% dependent on future transactional drug sales or milestone-based licensing

Future monetization via oncology drug sales (intralesional PV-10) and potential licensing deals; milestone payments from partners represent near-term vector

No commercial pricing architecture established; future pricing will benchmark against melanoma/oncology therapies ($50K–$150K course); reimbursement risk is primary stress point

Unproven; if approved, orphan/niche oncology positioning could support premium pricing, but payer pushback and competitive alternatives constrain power; rating: moderate-low

7.3% Gross Margin (Thin (<20%))

No free-rider leakage applicable; pre-revenue company with no subscription base; patient/clinical trial attrition is the analogous retention risk

Lean headcount (~10–20 employees); revenue growth post-approval would require commercial team buildout, making early commercialization headcount-linear

High marginal cost pre-commercialization due to clinical trial expenditure; post-approval, manufacturing scale and sales force create semi-fixed cost leverage

Not applicable; Provectus is not a franchise business model

At 10x scale (post-approval), CAC would involve oncologist detailing and hospital formulary adoption; unit economics depend heavily on reimbursement rates achieved

No network effects present; pharmaceutical drug adoption is linear and physician-driven, not network-compounding

-789.3% Return on Assets (Negative equity)

Moderate-high recession resistance for oncology drugs once commercialized; cancer treatment is non-discretionary; however, pre-revenue stage creates existential funding risk in downturns

Oncologists and dermatologists treating melanoma and hepatocellular carcinoma patients; concentrated in academic and specialty cancer centers

Hospital formulary committees and oncology group purchasing organizations; payer/insurer approval gatekeepers represent secondary critical segment

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

9.0% CapEx / Revenue (Moderate-CapEx)

0000315545

PVCT